Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Decrease in Short Interest

Posted by Brian Himes on Nov 11th, 2026

Enlivex Therapeutics Ltd. (NASDAQ:ENLV – Get Free Report) was the target of a large drop in short interest during the month of October. As of October 30th, there was short interest totaling 22,618 shares, a drop of 85.8% from the October 15th total of 159,295 shares. Based on an average trading volume of 48,253 shares, the days-to-cover ratio is currently 0.5 days. Approximately 1.7% of the company’s shares are short sold.

Institutional Trading of Enlivex Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its stake in Enlivex Therapeutics by 53.2% during the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after purchasing an additional 45,303 shares during the period. WINTON GROUP Ltd acquired a new stake in shares of Enlivex Therapeutics in the second quarter valued at $55,000. Finally, Susquehanna International Group LLP raised its stake in shares of Enlivex Therapeutics by 1,428.5% in the second quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock valued at $87,000 after acquiring an additional 147,334 shares in the last quarter. Institutional investors and hedge funds own 1.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ENLV. Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Zacks Research lowered shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Tuesday, September 22nd. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $4,800.00.

Check Out Our Latest Stock Analysis on ENLV

Enlivex Therapeutics Stock Performance

Shares of NASDAQ ENLV traded up $0.01 during mid-day trading on Wednesday, reaching $1.21. 17,022 shares of the company’s stock were exchanged, compared to its average volume of 24,488. The firm has a market capitalization of $1.84 million, a price-to-earnings ratio of -0.01 and a beta of 1.63. Enlivex Therapeutics has a 52-week low of $1.20 and a 52-week high of $434.40. The company’s 50-day moving average is $7.51 and its 200-day moving average is $131.49.

About Enlivex Therapeutics

(Get Free Report)

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore balance to dysregulated immune responses. The company’s approach is intended to address conditions in which excessive or uncontrolled inflammation contributes to disease progression. Enlivex’s lead product candidate is Allocetra-OTS, an off-the-shelf cell therapy made from apoptotic cells. The therapy is designed to reprogram the immune system toward a balanced state by helping regulate the activity of immune cells, including macrophages.